Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12599943 | 0.83 | GABRA1 (0.37) | HTR2AHTR2CLMNATP53HTT | |
| SCHEMBL24989671 | 0.80 | CES2 (0.41) | — | |
| SCHEMBL22787280 | 0.77 | — | — | |
| SCHEMBL20097032 | 0.76 | TSHR (0.38) | HTR2AHTR2C | |
| SCHEMBL20072387 | 0.75 | LMNA (0.44) | LMNATP53HTTPSEN1PSEN2 | |
| SCHEMBL24420896 | 0.75 | LMNA (0.31) | LMNATP53HTT | |
| SCHEMBL24039916 | 0.75 | CYP1A2 (0.39) | HTR2CLMNA | |
| SCHEMBL18780464 | 0.73 | KCNH2 (0.37) | HTR2AHTR2C | |
| SCHEMBL22154769 | 0.73 | GABRA1 (0.39) | HTR2AHTR2CLMNATP53HTT | |
| SCHEMBL22303592 | 0.72 | PSEN1 (0.41) | LMNATP53HTTPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-9630978-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | HTR2A 4349/4885HTR2C 4095/4885LMNA 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.